

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 996 468 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
21.05.2003 Bulletin 2003/21

(51) Int Cl.7: **A61K 47/48, A61P 23/00**

(86) International application number:
PCT/GB98/03001

(21) Application number: **98946571.1**

(22) Date of filing: **07.10.1998**

(87) International publication number:
WO 99/017806 (15.04.1999 Gazette 1999/15)

(54) **CONJUGATES OF GALACTOSE-BINDING LECTINS AND CLOSTRIDIAL NEUROTOXINS AS ANALGESICS**

GALAKTOSE-BINDENDE LEKTINE KONJUGATE MIT CLOSTRIDIALE NEUROTOXINE ,WIE ANALGETIKA

CONJUGUES DE LECTINES FIXATRICES DE GALACTOSE ET DE NEUROTOXINES CLOSTRIDIALES, UTILISES COMME ANALGESIQUES

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **08.10.1997 GB 9721189**

(43) Date of publication of application:
03.05.2000 Bulletin 2000/18

(73) Proprietors:
• **THE SPEYWOOD LABORATORY LTD.**
London W8 5HH (GB)
• **MICROBIOLOGICAL RESEARCH AUTHORITY**
Salisbury, Wiltshire SP4 0JG (GB)

(72) Inventors:
• **DUGGAN, Michael, John**
London SW1V 4BL (GB)
• **CHADDOCK, John, Andrew**
Hampshire RG24 8TE (GB)

(74) Representative: **MacLean, Martin Robert et al**
Mathys & Squire
100 Gray's Inn Road
London WC1X 8AL (GB)

(56) References cited:
WO-A-94/28923 **WO-A-95/32738**
WO-A-96/33273 **WO-A-97/18790**
WO-A-98/07864

• **STREIT, WOLFGANG J. ET AL: "Histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat" J. HISTOCHEM. CYTOCHEM. (1985), 33(10), 1042-52 CODEN: JHCYAS;ISSN: 0022-1554, 1985, XP002091075**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

Technical field

[0001] This invention relates to a class of novel agents that are able to modify nociceptive afferent function. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibres. The agent may be used in or as a pharmaceutical for the treatment of pain, particularly chronic pain.

Background

[0002] The sensation of pain due to injury or disease is carried from the periphery to the brain by a multi-neuronal pathway. The first part of this system comprises the primary nociceptive afferents that form synapses with secondary neurones in the dorsal horn of the spinal cord, or the nuclei of the cranial nerves. These synapses pass on the incoming information by the release of neurotransmitters and neuromodulators such as glutamate and substance P. These synapses are, therefore, possible sites for intervention to alleviate pain, indeed one of the modes of action of the opiate analgesics is to down-modulate neurotransmitter release at these synapses.

[0003] Unfortunately, the opiates have a number of limitations as drugs. Firstly, there are a number of chronic pain conditions for which the opiates are not effective. Secondly, the opiates have a number of side effects that are mediated both peripherally (constipation) and centrally (respiratory depression and euphoria) which present problems for long term use.

[0004] There is, therefore, a need for the development of new pharmaceuticals for the treatment of pain, particularly chronic pain.

[0005] One approach to this problem is the use of new agents containing fragments of clostridial neurotoxins (WO96/33273).

[0006] The clostridial neurotoxins are proteins with molecular masses of the order of 150 kDa. They are produced by various species of bacterium of the genus *Clostridium*, most importantly *C. tetani* and several strains of *C. botulinum*. There are at present eight different classes of the neurotoxins known: tetanus toxin, and botulinum neurotoxin in its serotypes A, B, C₁, D, E, F and G, and they all share similar structures and modes of action. The clostridial neurotoxins are synthesised by the host bacterium as single polypeptides that are modified post-translationally to form two polypeptide chains joined together by a disulphide bond. The two chains are termed the heavy chain (H), which has a molecular mass of approximately 100 kDa, and the light chain (L), which has a molecular mass of approximately 50 kDa.

Two distinct functions can be identified within the H-

chain; binding and translocation. The carboxy-terminal half (H_C) is involved in the high affinity, neurospecific binding of the toxin to cell surface acceptors, whilst the amino-terminal half (H_N) is central to the translocation of the toxin into the neuronal cell. For botulinum neurotoxin type A these domains are considered to reside within amino acid residues 872-1296 for the H_C, amino acid residues 449-871 for the H_N and residues 1-448 for the LC. The minimal domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem. Vol.267, No.21, July 1992, pages 14721-14729. The eight distinct neurotoxin light chains (L) are highly specific zinc-dependent endopeptidases which each hydrolyse different but specific peptide bonds in one of three substrate proteins, synaptobrevin, syntaxin or SNAP-25. These substrates are important components of the neurosecretory machinery. The hydrolytic activity of the clostridial toxins results in a prolonged muscular paralysis. The functions of all three identified domains are necessary for the toxic activity of the clostridial endopeptidases.

[0007] Some of the clostridial endopeptidases, most notably botulinum neurotoxin type A, have been used as pharmaceutical agents for the treatment of a range of muscle dystonias. The flaccid paralysing action of the native botulinum toxins makes them appropriate for this use.

[0008] The use of fragments of clostridial neurotoxins for the desired purpose of analgesia is dependent on the invention of conjugates, or derivatives of these molecules, with a specific binding activity that will deliver the L-chain endopeptidase to the nociceptive afferent neurons in preference to other neurones in the relevant anatomical locus. Delivery of these conjugates includes binding to the cell surface, internalisation via an endosomal compartment and translocation of the clostridial endopeptidase activity into the cytosol.

[0009] Targeting of extracellular species to specific intracellular locations following endocytosis involves an appreciation of a number of possible targeting strategies. It is understood that early endosomes are part of the key sorting mechanisms of the cell, routing species to late endosome (and onto lysosomes for degradation), recycling to the cell surface or to the Trans-Golgi Network. Intracellular routing determinants have been suggested that determine the pathway and final destination of particular species (Mellman, 1996, Annu. Rev. Cell Biol., 12, 575-625).

[0010] Current data suggests that translocation of native clostridial neurotoxins occurs from an acidic intracellular compartment, though the exact location and nature of the compartment is unknown (Montecucco & Schiavo, 1994, Mol. Micro. 13, 1-8). In patent WO96/33273 it is proposed that for an agent to be effective, the agent must target to an appropriate compartment for translocation of the toxin. As an example of specific intracellular targeting, internalisation of the NGF-receptor is by specific endocytosis and retrograde

routing (initiated by receptor-ligand complex), via acidic endosomes to the cell body, and an agent incorporating NGF is given in support of WO96/33273.

[0011] WO 96 33273 describes agents for the treatment of pain, wherein a modified clostridial toxin is covalently bound, directly or via a spacer, to a Targeting Moiety. The Targeting Moiety directs the agent to peripheral sensory afferents.

[0012] Streit *et al.*, J. Histochem. Cytochem. (1985), 33(10), pages 1042-1052, describes the intracellular histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of a rat.

Statement of Invention

[0013] The present invention relates to an agent that can reduce and preferably prevent the transmission of pain signals from the periphery to the central nervous system, thereby alleviating the sensation of pain. Specifically, the invention can provide an agent that can reduce and preferably prevent the transmission of pain signals from nociceptive afferents to projection neurones. More specifically, the invention can provide an agent that can inhibit the exocytosis of at least one neurotransmitter or neuromodulator substance from at least one category of nociceptive afferents.

[0014] In one aspect of the invention, an agent is provided which can be administered to the spinal cord, and which can inhibit the release of at least one neurotransmitter or neuromodulator from the synaptic terminals of nociceptive afferents terminating in that region of the spinal cord.

[0015] In a second aspect of the invention, there is provided an agent which can specifically target defined populations of afferent neurones, so that the effect of the agent is limited to that cell type.

[0016] In a third aspect of the invention, there is provided the use of an agent as above for the manufacture of a medicament for the treatment of pain.

[0017] In a fourth aspect of the invention, the agent can be expressed recombinantly as a fusion protein that includes the required components of the agent.

Definitions

[0018] Without wishing to be limited by the definitions set down, it is intended in this description that the following terms have the following meanings:

[0019] Light chain means the smaller of the two polypeptide components of any of the clostridial neurotoxins. It is commonly referred to as the L-chain or simply L. An L-chain has a molecular mass of approximately 50 kDa, and it is a metalloprotease exhibiting high substrate specificity for vesicle and/or plasma membrane associated proteins involved in the exocytotic process.

[0020] Heavy chain means the larger of the two polypeptide components of any of the clostridial neuro-

toxins. It is commonly referred to as H-chain or simply H and has a molecular mass of approximately 100 kDa.

[0021] H_C fragment means a peptide derived from the H-chain of a clostridial neurotoxin which is responsible for binding of the native holotoxin to cell surface acceptor(s) involved in the intoxicating action of clostridial toxin prior to internalisation of the toxin into the cell. It may be approximately equivalent to the carboxy-terminal half of the H-chain, or the domain corresponding to that fragment in the intact H-chain.

[0022] H_N fragment means a fragment derived from the H-chain of a clostridial neurotoxin approximately equivalent to the amino-terminal half of the H-chain, or the domain corresponding to that fragment in the intact H-chain. It is characterised as:

A portion of the H-chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell.

The domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell.

The domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH.

The domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone.

[0023] LH_N means a fragment derived from a clostridial neurotoxin that contains the L-chain, or a functional fragment thereof, coupled to a H_N fragment.

[0024] BoNT/A means botulinum neurotoxin serotype A, and is a neurotoxin produced by *Clostridium botulinum*; it has a molecular mass of approximately 150kDa.

[0025] LH_N/A is LH_N that is derived from *Clostridium botulinum* neurotoxin type A.

[0026] Targeting Moiety (TM) means any chemical structure of an agent which functionally interacts with a binding site causing a physical association between the agent and the surface of a primary sensory afferent.

[0027] Primary sensory afferent is a nerve cell that can carry sensory information from the periphery towards the central nervous system.

[0028] Primary nociceptive afferent is a nerve cell that can carry sensory information from the periphery towards the central nervous system, where that information can result in a sensation of pain.

[0029] Lectin is any protein that binds to oligosaccharide structures.

[0030] Galactose-binding lectin is a lectin that binds to oligosaccharide structures in which the terminal residue is derived from galactose or N-acetylgalactosamine.

Detailed Description of the Invention

[0031] It can be seen from this disclosure that an agent for reducing or preventing the transmission of pain signals from peripheral, nociceptive afferent neurones to projection neurones has many potential applications in the reduction of the sensation of pain, particularly of severe chronic pain.

[0032] Lectins are a class of proteins, often glycoproteins, that bind to carbohydrate structures. Lectins are found across the whole range of life forms from viruses to mammals. The most commonly exploited sources are the abundant lectins found in the seeds of plants. Lectins have previously been labelled and used as cell surface markers.

[0033] According to the invention, there is provided an agent that can inhibit the release of at least one neurotransmitter or neuromodulator or both from the synaptic terminals of nociceptive afferents.

[0034] It is known that such an agent can be produced based on the use of fragments of clostridial neurotoxin conjugated to a targeting ligand (WO96/33273). Given the known complexity of intracellular transport and the constraints on construct requirements, it is surprising that conjugates between toxin fragments and a specific sub-class of lectins that bind only to galactosyl residues form agents to produce analgesics that are particularly potent and selective. Inventions incorporating such lectins are the subject of this disclosure and several examples are provided.

[0035] One example of a class of plant-derived, galactose-binding lectins are those that can be purified from the seeds of the genus *Erythrina*. These lectins have been characterised to exist predominantly as non-covalent dimeric proteins with total molecular weights of approximately 60 kDa. Lectins have been isolated from several *Erythrina* species including: *E. corallodendron* (Gilboa-Garber and Mizrahi, 1981, Can. J. Biochem. 59, 315-320), *E. cristagalli* (Iglesias et al., 1982, Eur. J. Biochem. 123, 247-252), *E. indica* (Horejsi et al., 1980, Biochim. Biophys. Acta 623, 439-448), *E. arborescens*, *E. suberosa*, *E. lithosperma* (Bhattacharyya et al., 1981, Archiv. Biochem. Biophys. 211, 459-470) *E. caffra*, *E. flabelliformis*, *E. latissima*, *E. lysistemon*, *E. humeana*, *E. perrieri*, *E. stricta*, and *E. zeyheri* (Lis et al., 1985, Phytochem. 24, 2803-2809).

[0036] These lectins have been analysed for their selectivity for saccharide binding (see e.g. Kaladas et al., 1982, Archiv. Biochem. Biophys. 217, 624-637). They have been found to bind preferentially to oligosaccharides with a terminal β -D-galactosyl residue.

[0037] A second example of a plant-derived, galactose-binding lectin with the desired binding specificity can be obtained from *Glycine max* (soy) beans. This lectin (soya bean agglutinin, SBA) is a tetrameric protein with a total molecular weight of approximately 110 kDa. It binds to oligosaccharides containing galactose or N-acetylgalactosamine residues.

[0038] An example of a galactose-binding lectin from bacteria is PA-I, obtained from *Pseudomonas aeruginosa*. PA-I is a D-galactosephilic lectin with a molecular weight of about 13 kDa and it binds to galactose-containing oligosaccharides (Gilboa-Garber and Mizrahi, 1981, Can. J. Biochem. 59, 315-320).

[0039] These and other lectins of the sub-class of galactose-binding lectins can be used as targeting moieties (TM) for conjugates of the type described in WO96/33273. The requirements for TMs in these agents are that they show specificity for the primary sensory afferents over other spinal nerves and that they lead to the internalisation of the agents into an appropriate intracellular compartment. The lectins of this invention fulfil these criteria. Surprisingly, in comparison to other lectins of WO96/33273, they can fulfil these criteria more efficiently and can provide agents with enhanced selectivity for nociceptive afferent neurosecretion.

[0040] Thus, in one embodiment of the invention a galactose-binding lectin is conjugated, using linkages that may include one or more spacer regions, to a derivative of the clostridial neurotoxins.

[0041] In another embodiment of the invention the agent is expressed in a recombinant form as a fusion protein. The fusion protein may be derived from nucleic acid encoding an appropriate fragment of a galactose-binding lectin, in addition to any desired spacer domains, with nucleic acid encoding all or part of a polypeptide of one serotype of neurotoxin. Such a nucleic acid may be a chimera derived from the nucleic acid encoding polypeptides from more than one serotype.

[0042] In another embodiment of the invention the required LH_N , which may be a hybrid of an L and H_N from different clostridial toxin serotypes, is expressed as a recombinant fusion protein with the galactose-binding lectin, and may also include one or more spacer regions.

[0043] In a further embodiment of the invention the required TM, L or LH_N and translocation domain components may be separately expressed in a recombinant form and subsequently linked, covalently or non-covalently, to provide the desired agent.

[0044] In a further embodiment of the invention the required translocation domain may be of a non-clostridial origin, comprising instead a peptide or other entity capable of similar or enhanced function. Examples would include, but not be restricted to, the translocation domain of diphtheria toxin (O'Keefe et al., Proc. Natl. Acad. Sci. USA (1992) **89**, 6202-6206; Silverman et al., J. Biol. Chem. (1993) **269**, 22524-22532), the translocation domain of *Pseudomonas* exotoxin type A (Prior et al. Biochemistry (1992) **31**, 3555-3559), the translocation domains of anthrax toxin (Blanke et al. Proc. Natl. Acad. Sci. USA (1996) **93**, 8437-8442) and a variety of fusogenic or hydrophobic peptides of translocating function (Plank et al. J. Biol. Chem. (1994) **269**, 12918-12924).

Exploitation in Industry

[0045] The agent described in this invention can be used *in vivo*, either directly or as a pharmaceutically acceptable salt, for treatment of pain.

[0046] For example, an agent according to the invention can be administered by spinal injection (epidural or intrathecal) at the level of the spinal segment involved in the innervation of an affected organ for the treatment of pain. This is, for example, applicable in the treatment of deep tissue pain, such as chronic malignant pain.

[0047] The present invention will now be described by reference to the following examples together with the Figures that show the following:

Figure 1. SDS-PAGE analysis of fractions from ExL-LH_N/A purification scheme

Figure 2. Cleavage of SNAP-25 by ExL-LH_N/A

Figure 3. SDS-PAGE analysis of fractions from EcL-LH_N/A purification scheme

Figure 4 SDS-PAGE analysis of fractions from SBA-LH_N/A purification scheme

Figure 5 Native gel analysis of ExL- and SBA-LH_N/A

Figure 6 Activity of ExL-LH_N/A on release of neurotransmitter from eDRG and eSC neurons

Figure 7 Activity of SBA-LH_N/A on release of neurotransmitter from eDRG and eSC neurons

Figure 8 Activity of WGA-LH_N/A on release of neurotransmitter from eDRG and eSC neurons

Figure 9 Activity of ExL-LH_N/A in an *in vivo* electrophysiology model of analgesia

Figure 10 Activity of ExL-LH_N/A in an *in vivo* behavioural model of analgesia

Example 1. The Production of a conjugate between a lectin from *Erythrina cristagalli* and LH_N/A.

Materials

[0048] Lectin from *E. cristagalli* (ExL) was obtained from Sigma Ltd.

[0049] LH_N/A was prepared essentially by the method of Shone C.C., Hambleton, P., and Melling, J. 1987, *Eur. J. Biochem.* **167**, 175-180.

[0050] SPDP was from Pierce Chemical Co.

[0051] PD-10 desalting columns were from Pharmacia.

[0052] Dimethylsulphoxide (DMSO) was kept anhydrous by storage over a molecular sieve.

[0053] Denaturing sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using gels and reagents from Novex

[0054] Immobilised lactose-agarose was obtained from Sigma Ltd.

[0055] Additional reagents were obtained from Sigma Ltd.

Methods

[0056] The lyophilised lectin was rehydrated in phosphate buffered saline (PBS) to a final concentration of 10 mg/ml. Aliquots of this solution were stored at -20°C until use.

[0057] The ExL was reacted with an equal concentration of SPDP by the addition of a 10 mM stock solution of SPDP in DMSO with mixing. After one hour at room temperature the reaction was terminated by desalting into PBS over a PD-10 column.

[0058] The thiopyridone leaving group was removed from the product by reduction with dithiothreitol (DTT, 5 mM, 30 min). The product of this reaction was analysed spectrophotometrically at 280 nm and 343 nm to determine the degree of derivatisation achieved. The degree of derivatisation achieved was 0.8±0.06 mol/mol. The thiopyridone and DTT were removed by once again desalting into PBS over a PD-10 column.

[0059] The LH_N/A was desalted into PBSE (PBS containing 1 mM EDTA). The resulting solution (0.5-1.0 mg/ml) was reacted with a four- or five-fold molar excess of SPDP by addition of a 10 mM stock solution of SPDP in DMSO. After 3 h at room temperature the reaction was terminated by desalting over a PD-10 column into PBS.

[0060] A portion of the derivatised LH_N/A was removed from the solution and reduced with DTT (5 mM, 30 min). This sample was analysed spectrophotometrically at 280 nm and 343 nm to determine the degree of derivatisation. The degree of derivatisation achieved was 2.26±0.10 mol/mol.

[0061] The bulk of the derivatised LH_N/A and the derivatised ExL were mixed in proportions such that the ExL was in greater than three-fold molar excess. The conjugation reaction was allowed to proceed for >16 h at 4°C.

[0062] The product mixture was centrifuged to clear any precipitate that had developed. The supernatant was concentrated by centrifugation through concentrators (with 10000-50000 molecular weight exclusion limit) prior to a two step purification strategy. As the first step, the concentrated material was applied to a Superose 12 column on an FPLC chromatography system (Pharmacia). The column was eluted with PBS and the elution profile followed at 280 nm.

[0063] Fractions were analysed by SDS-PAGE on 4-20% polyacrylamide gradient gels, followed by staining with Coomassie Blue. The major band of conjugate has an apparent molecular mass of between 130-160 kDa; this is separated from the bulk of the remaining unconjugated LH_N/A and more completely from the uncon-

jugated ExL. Fractions containing conjugate were pooled prior to the second chromatography step; immobilised lactose-agarose. Selected post-Superose-12 fractions were applied to PBS-washed lactose-agarose and incubated for 2 hours at 4°C to facilitate binding. Lectin-containing proteins (i.e. ExL-LH_N/A conjugate) remained bound to the agarose during subsequent washing with PBS to remove contaminants (predominantly unconjugated LH_N/A). ExL-LH_N/A conjugate was eluted from the column by the addition of 0.3M lactose (in PBS) and the elution profile followed at 280 nm. The fractions containing conjugate were pooled, dialysed against PBS, and stored at 4°C until use.

[0064] In figure 1 is illustrated the SDS-PAGE profile during different stages in the conjugate purification scheme. Lanes 2 and 3 indicate ExL lectin and LH_N/A respectively prior to conjugation. Lanes 4, 5 & 6 represent conjugation mixture, post-Superose-12 and post-lactose affinity chromatography samples respectively. Lane 6 is therefore indicative of the profile of the final conjugate material. Molecular weight markers are represented in lanes 1 & 7 with sizes indicated on the figure. [0065] On the SDS-PAGE gel there are bands due to lectin alone in fractions containing the conjugate, this material is probably due to the non-covalent homodimeric nature of the ExL; where only one monomer of ExL is covalently attached to the LH_N/A the other is dissociated from the complex by the SDS in the electrophoretic procedure giving rise to these bands. The absence of free lectin monomers was confirmed by native PAGE analysis and is illustrated in Figure 5. ExL-LH_N/A (lane 5) was analysed by non-denaturing PAGE. Samples were separated using 4-20% polyacrylamide gel for 6.75 hours, 125V, 4°C. The electrophoresis profile was compared to those of LH_N/A (lane 3) and ExL lectin only (lane 4). A range of marker proteins were analysed alongside; apoferritin (lane 6), β-amylase (lane 8), alcohol dehydrogenase (lane 7) and albumin (lane 9). Approximate molecular sizes are indicated.

Example 2. The production of a conjugate between a lectin from *Erythrina corallodendron* and LH_N/A.

[0066] The procedure for production of a conjugate between a lectin from *Erythrina corallodendron* and LH_N/A is essentially as described in Example 1 but with the following differences:

Materials

[0067] Lectin from *E. corallodendron* (EcL) was obtained from Sigma Ltd.

[0068] Figure 3 illustrates the purification scheme for the EcL-LH_N/A conjugate. Samples were applied to 4-20% polyacrylamide gradient gels and subjected to electrophoresis prior to staining with Coomassie blue. Lane 1 = molecular weight markers. Lane 2 represents the post-lactose affinity purified sample of EcL-LH_N/A.

Lane 3 is a sample of pre-lactose affinity purified (size-exclusion chromatography only) EcL-LH_N/A. Lane 4 is a sample of pre-lactose affinity purified ExL-LH_N/A.

Example 3. The Production of a conjugate between a lectin from *Glycine max* and LH_N/A

[0069] The procedure for production of a conjugate between a lectin from *Glycine max* and LH_N/A is essentially as described in Example 1 but with the following differences:

Materials

[0070] Lectin from *G. max* (SBA) was obtained from Sigma Ltd.

Method

[0071] For the affinity chromatography step an immobilised N-acetylgalactosamine (GalNAc) column was used and specific SBA-LH_N/A was eluted by the addition of 0.3M lactose.

Figure 4 illustrates SDS-PAGE profile changes during the purification scheme for SBA-LH_N/A. SBA-LH_N/A was purified from crude conjugate mixture by Superose-12 size-exclusion chromatography and immobilised N-acetylgalactosamine affinity chromatography. Samples were subjected to SDS-PAGE on 4-20% polyacrylamide gels. Lanes 6-8 were run in the presence of 0.1M DTT. Lanes 1 (&7) and 2 (&8) indicate SBA and SPDP-derivatised LH_N/A respectively, prior to conjugation. Lanes 3, 4 & 5 (&6) represent conjugation mixture, post-Superose-12 and post-affinity chromatography samples respectively. Lane 5 is therefore indicative of the profile of the final conjugate material. Molecular weight markers are represented in lanes Mr with sizes indicated on the figure.

[0072] The absence of free lectin monomers was confirmed by native non-denaturing PAGE analysis as illustrated in Figure 5. Samples were separated using 4-20% polyacrylamide gel for 6.75 hours, 125V, 4°C. The electrophoresis profile of SBA-LH_N/A (lane 1) was compared to those of SBA lectin only (lane 2) and LH_N/A (lane 3). A range of marker proteins were analysed alongside; apoferritin (lane 6), β-amylase (lane 8), alcohol dehydrogenase (lane 7) and albumin (lane 9). Approximate molecular sizes are indicated.

Example 4. Activity of ExL-LH_N/A in primary neuronal cultures

[0073] The dorsal root ganglia contain the cell bodies of primary nociceptive afferent neurons. It is well established that in primary *in vitro* cultures of this tissue the neurons retain many of the characteristics of the nociceptive afferent. These characteristics include the ability to release neuropeptides such as substance P in re-

sponse to chemical stimuli known to cause pain *in vivo* (e.g. capsaicin). Neurons anatomically adjacent to those of the DRG include those of the spinal cord. Cultures of SC neurons prepared from embryonic rats can be established *in vitro* and the release of neurotransmitter (^3H -glycine) under potassium stimulation can be assessed. As such, the eSC neurons represent a model cell for testing the selectivity of the agents described.

[0074] The selectivity of the ExL-LH_N/A agent for eDRG over eSC neurons is clearly illustrated in Figure 6. The dose curves document the effectiveness of ExL-LH_N/A in an *in vitro* cell culture model by comparing inhibition of neurotransmission in eDRG with eSC neurons.

Materials

[0075] Substance P enzyme linked immunosorbent assay kits were from Cayman Chemical Company.

[0076] Western blot reagents were obtained from Novex

[0077] Monoclonal antibody SMI-81 was from Sternberger Monoclonals Inc.

Methods

[0078] Primary cultures of dorsal root ganglion and embryonic spinal cord neurons were established following dissociation of the ganglia dissected from rat embryos (embryological age 12-15 days). For the preparation of eDRG neurons, the cells were plated into 12 well plates at an initial density of 3×10^5 cells/well in a medium containing NGF (100 ng/ml). After one day in culture, fresh medium containing cytosine arabinoside (10×10^{-6} M) was added to kill non-neuronal cells. After 2-4 days the cytosine arabinoside was removed. After several more days in culture the medium was replaced with fresh medium containing conjugate or LH_N.

[0079] For the preparation of eSC neurons, Cells were plated onto poly-D-lysine coated 12 well plates (Costar) at a density of 2×10^6 cells per well (1 ml/well). 'Plating' medium was MEM with Earles Salts (Sigma), containing 5% foetal bovine serum (FBS), 5% heat inactivated horse serum (HS), 0.6% dextrose, 1.5g/l NaHCO₃ and 2 mM L-glutamine. Cultures are incubated at 37°C with 10% CO₂. The medium was changed to 'feeding' medium (plating medium minus the FBS with N1 (Sigma) 1/50 supplement) after one day. When glial cells became almost confluent anti-mitotic agents (15 microgrammes /ml 5-fluoro-2'-deoxyuridine (FdU) and 35 microgrammes /ml uridine (U)) were added for a further 2-3 days. Cells were cultured for at least 3 weeks prior to use.

[0080] The cells were incubated with these agents for varying times and then tested for their ability to release the neurotransmitters glutamate and substance P (eDRG) or glycine (eSC). After the release assays were performed the cells were lysed and the hydrophobic pro-

teins were extracted by phase partitioning with Triton-X-114 following the method outlined in Boyd, Duggan, Shone and Foster (J. Biol. Chem. **270**, 18216-18218, 1995).

Substance P release assay

[0081] The release of endogenous substance P was effected by collecting cell supernatants after treating the cells for 5 min with either a physiological balanced salt solution or a balanced salt solution in which the potassium ion concentration had been raised to 100 mM with consequent reduction in the sodium ion concentration to maintain isotonicity. Total substance P was measured after extraction in 2 M acetic acid, 0.1% trifluoroacetic acid and subsequent dehydration. Substance P immunoreactivity was measured using an enzyme immunoassay kit (Cayman Chemical Company).

^3H Glutamate release assay

[0082] The release of glutamate was measured after loading the cells with ^3H glutamine as a radiotracer. The ^3H glutamine is converted to ^3H glutamate in the cell, and it is this ^3H glutamate that is taken up by synaptic vesicles and released upon depolarisation of the neuron. The cells are loaded with the ^3H glutamine (5×10^{-6} Ci/ml in HEPES-buffered MEM) for 2 h, then washed twice with HEPES-buffered MEM and thrice with balanced salt solution (BSS). Basal release was assessed with a 3 min incubation with BSS. Stimulated release was determined by a 3 min incubation with BSS in which the potassium concentration had been elevated to 80-100 mM with a consequent reduction in the sodium concentration to maintain isotonicity. All manipulations were performed at 37°C. The cells were lysed by the addition of Triton-X-100 (0.1%, v/v). For the basal and stimulated release superfusates the glutamate was separated from the glutamine by ion-exchange chromatography over Dowex-1 resin. The relevant fractions were analysed for ^3H content by liquid scintillation counting.

^3H Glycine release assay

[0083] The release of glycine was measured after loading the cells with ^3H glycine as a radiotracer. The ^3H glycine is taken up by synaptic vesicles and released upon depolarisation of the neuron. The cells are loaded with the ^3H glycine (2×10^{-6} Ci/ml in HEPES-buffered MEM) for 2 h, then washed once with HEPES-buffered MEM and thrice with balanced salt solution (BSS). Basal release was assessed with a 5 min incubation with BSS. Stimulated release was determined by a 5 min incubation with BSS in which the potassium concentration had been elevated to 56 mM with a consequent reduction in the sodium concentration to maintain isotonicity. All manipulations were performed at 37°C. The cells were lysed by the addition of 2 M acetic acid,

0.1% trifluoroacetic acid. Fractions were analysed for their ^3H content by liquid scintillation counting and inhibition of release determined.

[0084] Figure 6 illustrates the activity of ExL-LH_N/A on release of neurotransmitter from eDRG and eSC neurons. Both eDRG and eSC cultures were exposed to a range of ExL-LH_N/A concentrations (1 ml volumes) for three days. The percentage inhibition of eDRG substance P (n) and eSC [^3H]-glycine (?) release is in comparison to untreated controls. The data shown is representative of ≈ 3 determinations. IC₅₀ for eDRG was determined to be $3.66 \pm 0.92 \mu\text{g/ml}$. An inhibition of 50% was not obtained for eSC using the concentration range employed.

Western blotting

[0085] ExL-LH_N/A was applied to eDRG for 16 hours. After the determination of neurotransmitter release the cells were lysed by the addition of 2 M acetic acid, 0.1% trifluoroacetic acid and subsequently dehydrated. To extract the membrane proteins from these mixtures Triton-X-114 (10%, v/v) was added and incubated at 4°C for 60 min, the insoluble material was removed by centrifugation and the supernatants were then warmed to 37°C for 30 min. The resulting two phases were separated by centrifugation and the upper phase discarded. The proteins in the lower phase were precipitated with chloroform/methanol for analysis by Western blotting.

[0086] The extracted protein samples were applied to 4-20% polyacrylamide gradient gels and subjected to electrophoresis prior to transfer to nitrocellulose. Proteolysis of SNAP-25, a crucial component of the neurosecretory process and the substrate for the zinc-dependent endopeptidase activity of BoNT/A, was then detected by probing with an antibody (SMI-81) that recognises both the intact and cleaved forms of SNAP-25 (Figure 2). Proteins blotted onto nitrocellulose were probed with antibody SMI-81. Lanes 1-3, 4-6, 7-9 and 10-12 represent cells treated with medium, 40 microgrammes/ml ExL, 20 microgrammes/ml ExL and 40 microgrammes/ml LH_N/A respectively. Densitometric analysis of these data determined the %SNAP-25 cleavage to be 52.7% and 37.0% for 40 and 20 microgrammes/ml respectively.

Example 5. Activity of SBA-LH_N/A in primary neuronal cultures

[0087] Using methodology described in Example 4, the activity of SBA-LH_N/A in primary neuronal cultures was assessed. The selectivity of the SBA-LH_N/A conjugate for eDRG over eSC neurons is illustrated in Figure 7. Both eDRG and eSC cultures were exposed to a range of SBA-LH_N/A concentrations (1 ml volumes) for three days. The percentage inhibition of eDRG substance P (n) and eSC [^3H]-glycine (O) release is in comparison to untreated controls. The data is the mean of

three determinations \pm SE. The curves shown are representative of two experiments. IC₅₀ values for eDRG neurons were determined to be 1.84 and 7.6 microgrammes/ml. It is observed that SBA-LH_N/A exhibits a clear selectivity of the inhibition of neurotransmitter release from eDRG relative to eSC neurons. These data therefore confirm observations described for ExL-LH_N/A above and highlight the properties of galactose-specific lectins.

Example 7. Activity of WGA-LH_N/A in primary neuronal cultures

[0088] Using methodology described in Example 4, the activity of WGA-LH_N/A in primary neuronal cultures was assessed. WGA represents an example of a non-galactosyl targeted lectin and therefore serves as an indicator of the properties of conjugate that do not recognise galactosyl moieties. The lack of selectivity of the WGA-LH_N/A conjugate for eDRG over eSC neurons is illustrated in Figure 8. eDRG and eSC neurons were exposed to a range of concentrations of WGA-LH_N/A for 3 days prior to assay of stimulated release of neurotransmitter (substance P and glycine respectively). Each conjugate concentration was assessed in triplicate and results are expressed as percentage inhibition compared to untreated controls. Panels A and B represent dose response curves from one experiment representative of ≥ 3 for eDRG and eSC neurons respectively. Each point shown is the mean of three determinations \pm SE of the mean. IC₅₀ data for the effects of WGA-LH_N/A was calculated to be 0.34 ± 0.06 microgrammes /ml (eDRG) and 0.06 ± 0.09 microgrammes /ml (eSC), indicating the lack of C-fibre selectivity.

Example 8. Activity of ExL-LH_N/A in an electrophysiological model of pain

[0089] A dose of 45 microgrammes of ExL-LH_N/A in a 10 microlitres volume of vehicle was given by intrathecal injection to rats between lumbar sections L4-L5, 24 hours prior to electrophysiological analysis of neuronal activity. Animals were allowed to recover and movement was not restricted prior to sacrifice and analysis. The results from a group of 3 animals with 10 neurons recorded per animal, show that there was a 73% reduction in the C-fibre responses of the neurones (Figure 9A) although the stimulus threshold is only slightly elevated (Figure 9B). Inhibition of C-fibre responses would lead to a decrease in the transmission of pain signals and these data are indicative of the analgesic effect of conjugate ExL-LH_N/A. There was also a significant decrease in the A_δ response (Figure 9C). These fibres are also implicated in the transmission of noxious stimuli and this result emphasises the analgesic effect of ExL-LH_N/A. A_β neurons, a cell type that is not involved in transmission of noxious stimuli, were essentially unaltered in their responses to this stimulus (Figure 9D).

The lack of affect on the A_β-fibre neurons is indicative of the selectivity of ExL-LH_N/A for the neurons central to the transmission of pain signals.

Example 9. Activity of ExL-LH_N/A in behavioural models of pain

[0090] In an accepted *in vivo* model of pain, the mouse hotplate test, ExL-LH_N/A has been demonstrated to exhibit analgesic properties. Figure 10 illustrates the data obtained for ExL-LH_N/A where it is compared to a supramaximal dose of morphine. ExL-LH_N/A was applied intrathecally (30 microgrammes in a 5 microlitre vehicle volume) to each of a group of 10 mice and analgesic response in the hot plate test determined. Data is presented as hot plate latency (seconds) plotted against assay time (P = pre-treatment, 0-5 = hours post application). Onset of ExL-LH_N/A action had apparently reached a plateau at 1 hour that remained constant for at least 5 hours. The level of analgesia is similar to a supramaximal dose (50 microgrammes, 20X mouse EC₅₀) of morphine in this test, but is of much longer duration. This level of morphine achieves a maximal effect at 1 hour and then returns to control levels over a period of 5 hours. These data represent a clear indication of the analgesic potential of agents such as ExL-LH_N/A.

Materials

[0091] Adult outbred mice (MF1) of either sex, weight range 20 to 30g.

Methods

[0092] Test material is injected into the intrathecal space of anaesthetised mice using a 30 gauge disposable needle attached to a 50 microlitre Hamilton syringe. The site of injection was normally chosen to be between lumbar vertebrae 5 and 6. The needle is inserted into the tissue to one side of the vertebrae so that it slips into the groove between the spinous and transverse processes. The needle is then moved carefully forward to the intervertebral space. 5 microlitres of test material is then injected into the intrathecal space and the needle withdrawn. The skin incision is then closed with a single wound clip and the animal placed in a box to allow recovery.

Claims

1. An agent for the treatment of pain that comprises a galactose-binding lectin linked to a derivative of a clostridial neurotoxin, in which the derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating

activity.

2. An agent according to Claim 1 in which the membrane translocation domain is derived from the heavy chain of a clostridial toxin.
3. An agent according to Claim 1 in which the membrane translocation domain is derived from a non-clostridial source.
4. An agent according to any preceding Claim in which the lectin binds to oligosaccharides that contain terminal β-D-galactosyl residues
5. An agent according to any preceding Claim in which the lectin binds to oligosaccharides that contain terminal α-D-galactosyl residues
6. An agent according to any preceding Claim in which the lectin binds to oligosaccharides that contain N-acetylgalactosamine
7. An agent according to any previous Claim in which the lectin is derived from a species of plant.
8. An agent according to the previous Claim in which the lectin is derived from a species of the genus *Erythrina*.
9. An agent according to Claim 8 in which the lectin is derived from *E. cristagalli*.
10. An agent according to Claim 8 in which the lectin is derived from *E. corallodendron*.
11. An agent according to Claims 7 in which the lectin is obtained from *Glycine max*.
12. An agent according to Claims 7 in which the lectin is obtained from *Arachis hypogaea*.
13. An agent according to Claims 7 in which the lectin is obtained from *Bandeirea simplicifolia*.
14. An agent according to Claim 1-6 in which the lectin is of mammalian origin.
15. An agent according to Claim 1-6 in which the lectin is obtained from bacteria.
16. An agent according to Claim 15 in which the lectin is obtained from *Pseudomonas aeruginosa*.
17. An agent according to any preceding Claim in which the lectin has been produced using recombinant technology.
18. An agent according to any preceding Claim in which

the lectin has been enzymatically modified.

19. An agent according to any preceding Claim in which the lectin has been chemically modified.
20. An agent according to any preceding Claim wherein, if the heavy chain (H-chain) of a clostridial neurotoxin is present, the H_C domain of the H-chain is removed or modified.
21. An agent according to any preceding claim in which the H-chain, if present, is modified by chemical derivatisation to reduce or remove its native binding affinity for motor neurons.
22. An agent according to any of Claims 1-20 in which the H-chain, if present, is modified by mutation to reduce or remove its native binding affinity for motor neurons.
23. An agent according to any of Claims 1-20 in which the H-chain, if present, is modified by proteolysis.
24. An agent according to Claim 20 in which, if the H-chain is present, the H_C domain is completely removed leaving only the H_N-fragment of a clostridial neurotoxin.
25. An agent according to any preceding Claim in which the derivative of the clostridial neurotoxin, or fragment thereof, is obtained from botulinum neurotoxin.
26. An agent according to any preceding Claim in which the derivative of the clostridial neurotoxin, or fragment thereof, is obtained from botulinum neurotoxin type A.
27. An agent according to Claims 1-25 in which the derivative of the clostridial neurotoxin, or fragment thereof, is obtained from botulinum neurotoxin type B.
28. An agent according to any of Claims 1, 2, or 4-25 (except when dependent on Claim 3) which is formed by the coupling of a galactose-binding lectin to the LH_N fragment of botulinum neurotoxin type A.
29. An agent according to Claim 28 which is formed by the coupling of the galactose-binding lectin from *Erythrina cristagalli* to the LH_N fragment of botulinum neurotoxin type A.
30. An agent according to Claim 28 which is formed by the coupling of the galactose-binding lectin from *Erythrina corallodendron* to the LH_N fragment of botulinum neurotoxin type A.
31. An agent according to Claim 28 which is formed by the coupling of the galactose-binding lectin from *Glycine max* to the LH_N fragment of botulinum neurotoxin type A.
32. An agent according to any preceding Claim in which the H-chain, if present, is obtained from a different clostridial neurotoxin than that from which the L-chain is obtained.
33. An agent according to Claim 32 in which the H-chain is obtained from botulinum neurotoxin type A and the L-chain from botulinum neurotoxin type B.
34. An agent according to Claim 32 in which the H-chain is obtained from botulinum neurotoxin type A and the L-chain from tetanus neurotoxin.
35. An agent according to Claims 33 and 34 in which the H-chain component is the H_N fragment of botulinum neurotoxin type A.
36. An agent according to any preceding Claim in which the L-chain or L-chain fragment is linked to the H-chain, if present, by a direct covalent linkage.
37. An agent according to any of Claims 1-35 in which the L-chain or L-chain fragment is linked to the H-chain, if present, by a covalent linkage which includes one or more spacer regions.
38. An agent according to any preceding Claim in which the clostridial neurotoxin derivative incorporates polypeptides produced by recombinant technology.
39. An agent according to any preceding Claim in which the lectin is linked to the clostridial neurotoxin-derived component by a direct covalent linkage.
40. An agent according to any of Claims 1-38 in which the lectin is linked to the clostridial neurotoxin-derived component by a covalent linkage which includes one or more spacer regions.
41. An agent according to any preceding Claim in which the lectin and clostridial neurotoxin components are produced as a recombinant fusion protein.
42. An agent according to any preceding Claim in which the lectin protein has been modified from its native polypeptide sequence whilst retaining an ability for the protein to bind oligosaccharide structures, in which the terminal residue is derived from galactose or N-acetylgalactosamine.
43. An agent according to Claim 42 in which the protein modification results from modification of the nucleic acid coding for the lectin protein from its native se-

quence.

44. A method for obtaining an agent according to any preceding Claim which comprises the covalent attachment of a galactose-binding lectin to a derivative of a clostridial neurotoxin, in which the derivative of the clostridial neurotoxin comprises the L-chain or an L-chain fragment which includes the active proteolytic domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. 5
45. A method for obtaining an agent according to any of Claims 1-43 which comprises the covalent attachment of a galactose-binding lectin to a derivative of a clostridial neurotoxin with the inclusion of one or more spacer regions, in which the derivative of the clostridial neurotoxin comprises the L-chain or an L-chain fragment which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. 10
46. A method according to Claim 44 or 45 in which the membrane translocation domain is derived from the heavy chain of a clostridial toxin. 15
47. A method according to Claim 44 or 45 in which the membrane translocation domain is derived from a non-clostridial source. 20
48. A method for obtaining an agent according to any of Claims 1-43 which comprises constructing a genetic construct which codes for the agent, incorporating said construct into a host organism and expressing the construct to produce the agent. 25
49. Use of the agent of any one of Claims 1-43 in the manufacture of a medicament for controlling the transmission of sensory information from a primary sensory afferent to a projection neuron. 30
50. Use of the agent of any one of Claims 1-43 in the manufacture of a medicament for controlling the transmission of sensory information from a primary nociceptive afferent to a projection neuron. 35
51. Use according to Claim 49 or Claim 50 wherein the transmission is the release of a neurotransmitter or neuromodulator. 40
52. Use of the agent of any one of Claims 1-43 in the manufacture of a medicament for controlling the sensation of pain. 45
53. Use of the agent according to any one of Claims 1-43 in the manufacture of a medicament for the alleviation and/or prevention of pain. 50

Patentansprüche

1. Mittel zur Behandlung von Schmerz, das ein Galactose bindendes Lektin umfasst, angebunden an ein Derivat eines Clostridien-Neurotoxins, worin das Derivat des Clostridien-Neurotoxins die L-Kette oder ein Fragment derselben umfasst, welches die aktive proteolytische Enzymdomäne der leichten Kette (L-Kette) umfasst, verbunden mit einem Molekül oder einer Domäne mit Membran-translozierender Aktivität (membrane translocating activity). 5
2. Mittel gemäß Anspruch 1, worin die Membran-translozierende Domäne aus der schweren Kette eines Clostridien-Toxins abgeleitet ist. 10
3. Mittel gemäß Anspruch 1, worin die Membran-translozierende Domäne aus einer Nicht-Clostridien-Quelle abgeleitet ist. 15
4. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin an Oligosaccharide bindet, welche endständige β -D-Galactosylreste enthalten. 20
5. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin an Oligosaccharide bindet, die endständige α -D-Galactosylreste enthalten. 25
6. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin an Oligosaccharide bindet, die N-Acetylgalactosamin enthalten. 30
7. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin von einer Spezies an Pflanzen abgeleitet ist. 35
8. Mittel gemäß dem vorstehenden Anspruch, worin das Lektin von einer Spezies der Gattung *Erythrina* abgeleitet ist. 40
9. Mittel gemäß Anspruch 8, worin das Lektin von *E. cristagalli* abgeleitet ist. 45
10. Mittel gemäß Anspruch 8, worin das Lektin von *E. corallodendron* abgeleitet ist. 50
11. Mittel gemäß Anspruch 7, worin das Lektin aus *Glycine max* erhalten wird. 55
12. Mittel gemäß Anspruch 7, worin das Lektin aus *Arachis hypogaea* erhalten wird.
13. Mittel gemäß Anspruch 7, worin das Lektin aus *Bandeirea simplicifolia* erhalten wird.
14. Mittel gemäß Anspruch 1 bis 6, worin das Lektin aus einem Säuger stammt.

15. Mittel gemäß Anspruch 1 bis 6, worin das Lektin aus Bakterien erhalten wird.
16. Mittel gemäß Anspruch 15, worin das Lektin aus *Pseudomonas aeruginosa* erhalten wird. 5
17. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin unter Anwendung rekombinanter Techniken erzeugt worden ist. 10
18. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin enzymatisch modifiziert worden ist. 15
19. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin chemisch modifiziert worden ist. 20
20. Mittel gemäß einem der vorstehenden Ansprüche, worin dann, wenn die schwere Kette (H-Kette) des Clostridien-Neurotoxins vorhanden ist, die Hc-Domäne der H-Kette entfernt oder modifiziert ist. 25
21. Mittel gemäß einem der vorstehenden Ansprüche, worin die H-Kette, falls vorhanden, mittels chemischer Derivatisierung zur Verringerung oder Entfernung ihrer nativen Bindungsaffinität für motorische Neuronen modifiziert ist. 30
22. Mittel gemäß einem der Ansprüche 1 bis 20, worin die H-Kette, falls vorhanden, mittels Mutation zur Verringerung oder Entfernung ihrer nativen Bindungsaffinität für motorische Neuronen modifiziert worden ist. 35
23. Mittel gemäß einem der Ansprüche 1 bis 20, worin die H-Kette, falls vorhanden, mittels Proteolyse modifiziert worden ist. 40
24. Mittel gemäß Anspruch 20, worin dann, wenn die H-Kette vorhanden ist, die H_C-Domäne vollständig entfernt worden ist, um nur das H_N-Fragment eines Clostridien-Neurotoxins zu belassen. 45
25. Mittel gemäß einem der vorstehenden Ansprüche, worin das Derivat des Clostridien-Neurotoxins oder Fragment desselben aus einem Botulinus-Neurotoxin erhalten wird. 50
26. Mittel gemäß einem der vorstehenden Ansprüche, worin das Derivat des Clostridien-Neurotoxins oder Fragment desselben aus dem Botulinus-Neurotoxin Typ A erhalten wird. 55
27. Mittel gemäß einem der Ansprüche 1 bis 25, worin das Derivat des Clostridium-Neurotoxins oder Fragment desselben aus dem Botulinus-Neurotoxin Typ B erhalten wird.
28. Mittel nach einem der Ansprüche 1, 2 oder 4 - 25 (ausgenommen dann, wenn diese von Anspruch 3 abhängen), das durch Kuppeln eines Galactose bindenden Lektins an das LH_N-Fragment des Botulinus-Neurotoxins Typ A gebildet wird.
29. Mittel gemäß Anspruch 28, das durch Kuppeln des Galactose bindenden Lektins aus *Erythrina cristagalli* an das LH_N-Fragment des Botulinus-Neurotoxins Typ A gebildet wird.
30. Mittel gemäß Anspruch 28, das durch Kuppeln des Galactose bindenden Lektins aus *Erythrina corallodendron* an das LH_N-Fragment von Botulinus-Neurotoxin Typ A erhalten wird.
31. Mittel gemäß Anspruch 28, das durch das Kuppeln des Galactose bindenden Lektins aus *Glycine max* an das LH_N-Fragment des Botulinus-Neurotoxins Typ A erhalten wird.
32. Mittel gemäß einem der vorstehenden Ansprüche, worin die H-Kette, falls vorhanden, aus einem anderen Clostridien-Neurotoxin als demjenigen erhalten wird, aus dem die L-Kette erhalten wird.
33. Mittel gemäß Anspruch 32, worin die H-Kette aus dem Botulinus-Neurotoxin Typ A und die L-Kette aus dem Botulinus-Neurotoxin Typ B erhalten wird.
34. Mittel gemäß Anspruch 32, worin die H-Kette aus dem Botulinus-Neurotoxin Typ A und die L-Kette aus dem Tetanus-Neurotoxin erhalten wird.
35. Mittel gemäß Anspruch 33 und 34, worin die H-Kette als Komponente des HN-Fragment des Botulinus-Neurotoxins Typ A ist.
36. Mittel gemäß einem der vorstehenden Ansprüche, worin die L-Kette oder das L-Ketten-Fragment an die H-Kette, falls vorhanden, über eine direkte kovalente Bindung angebunden ist.
37. Mittel gemäß einem der Ansprüche 1 - 35, worin die L-Kette oder das L-Ketten-Fragment an die H-Kette, falls vorhanden, über eine kovalente Bindung angebunden ist, die einen oder mehrere Spacer-Bereiche umfasst.
38. Mittel gemäß einem der vorstehenden Ansprüche, worin das Derivat des Clostridien-Neurotoxins Polypeptide umfasst, erzeugt über rekombinante Techniken.
39. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin an die von dem Clostridien-Neurotoxin abgeleitete Komponente über eine direkte kovalente Bindung angebunden ist.

40. Mittel gemäß einem der Ansprüche 1 bis 38, worin das Lektin an die von dem Clostridien-Neurotoxin abgeleitete Komponente über eine kovalente Bindung angebunden ist, die eine oder mehrere Spacer-Bereiche umfasst.
41. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektin und die Clostridien-Neurotoxin-Komponenten als ein rekombinantes Fusionsprotein erzeugt werden.
42. Mittel gemäß einem der vorstehenden Ansprüche, worin das Lektinprotein aus seiner nativen Polypeptidsequenz modifiziert worden ist, während eine Fähigkeit des Proteins, an Oligosaccharidstrukturen zu binden, erhalten wurde, worin der endständige Rest von Galactose oder N-Acetylgalactosamin abgeleitet ist.
43. Mittel gemäß Anspruch 42, worin die Proteinmodifikation aus der Modifikation der Nukleinsäure herrührt, welche für das Lektinprotein in seiner nativen Sequenz kodiert.
44. Verfahren zum Erhalt eines Mittels gemäß einem der vorstehenden Ansprüche, das die kovalente Anbindung eines Galactose bindenden Lektins an ein Derivat eines Clostridien-Neurotoxins umfasst, worin das Derivat des Clostridien-Neurotoxins die L-Kette oder ein L-Ketten-Fragment umfasst, welches die aktive proteolytische Domäne der leichten Kette (L-Kette), angebunden an ein Molekül oder eine Domäne mit Membran-translozierender Aktivität, umfasst.
45. Verfahren zum Erhalt eines Mittels gemäß einem der Ansprüche 1 - 43, welches die kovalente Anbindung eines Galactose bindenden Lektins an ein Derivat eines Clostridien-Neurotoxins unter Einschluß einer oder mehrerer Spacer-Bereiche umfasst, worin das Derivat des Clostridien-Neurotoxins die L-Kette oder ein L-Ketten-Fragment umfasst, welches die aktive proteolytische Enzymdomäne der leichten Kette (L-Kette), angebunden an ein Molekül oder eine Domäne mit Membran-translozierender Aktivität, umfasst.
46. Verfahren gemäß Anspruch 44 oder 45, worin die Membran-translozierende Domäne aus der schweren Kette eines Clostridien-Toxins abgeleitet ist.
47. Verfahren gemäß Anspruch 44 oder 45, worin die Membran-translozierende Domäne aus einer Nicht-Clostridien-Quelle abgeleitet ist.
48. Verfahren zum Erhalt eines Mittels gemäß einem der Ansprüche 1 - 43, das das Konstruieren eines genetischen Konstrukts, welches für das Mittel ko-

diert, das Inkorporieren des Konstrukts in einen Wirtsorganismus und das Expressieren des Konstrukts zum Erzeugen des Mittels umfasst.

49. Verwendung des Mittels nach einem der Ansprüche 1 bis 43 bei der Herstellung eines Medikaments zum Steuern der Transmission sensorischer Information aus einer primären sensorischen Afferenz an ein Projektionsneuron.
50. Verwendung des Mittels nach einem der Ansprüche 1 - 43 bei der Herstellung eines Medikaments zum Steuern der Transmission sensorischer Information aus einer primären nocizeptiven Afferenz an ein Projektionsneuron.
51. Verwendung gemäß Anspruch 49 oder Anspruch 50, worin die Transmission die Freisetzung eines Neurotransmitters oder Neuromodulators darstellt.
52. Verwendung des Mittels nach einem der Ansprüche 1 - 43 bei der Herstellung eines Medikaments zur Steuerung des Schmerzempfindens.
53. Verwendung des Mittels gemäß einem der Ansprüche 1 - 43 bei der Herstellung eines Medikaments zur Erleichterung und/oder Vorbeugung von Schmerz.

Revendications

1. Agent pour le traitement de la douleur, qui comprend une lectine fixatrice de galactose liée à un dérivé d'une neurotoxine clostridiale, dans lequel le dérivé de la neurotoxine clostridiale comprend la chaîne L ou un fragment de celle-ci, qui inclut le domaine actif de l'enzyme protéolytique de la chaîne légère (L), lié à une molécule ou un domaine ayant une activité de translocation à travers la membrane.
2. Agent selon la revendication 1, dans lequel le domaine de translocation à travers la membrane est dérivé de la chaîne lourde d'une toxine clostridiale.
3. Agent selon la revendication 1, dans lequel le domaine de translocation à travers la membrane est dérivé d'une source non clostridiale.
4. Agent selon une revendication précédente quelconque, dans lequel la lectine se fixe sur des oligosaccharides qui contiennent des résidus terminaux de β -D-galactosyle.
5. Agent selon une revendication précédente quelconque, dans lequel la lectine se fixe sur des oligosaccharides qui contiennent des résidus terminaux de α -D-galactosyle.

6. Agent selon une revendication précédente quelconque, dans lequel la lectine se fixe sur des oligosaccharides qui contiennent de la N-acétylgalactosamine.
7. Agent selon une revendication précédente quelconque, dans lequel la lectine est dérivée d'une espèce de plante.
8. Agent selon la revendication précédente quelconque, dans lequel la lectine est dérivée d'une espèce du genre *Erythrina*.
9. Agent selon la revendication 8, dans lequel la lectine est dérivée de *E. cristagalli*.
10. Agent selon la revendication 8, dans lequel la lectine est dérivée de *E. corallodendron*.
11. Agent selon la revendication 7, dans lequel la lectine est obtenue à partir de *Glycine max*.
12. Agent selon la revendication 7, dans lequel la lectine est obtenue à partir d'*Arachis hypogaea*.
13. Agent selon la revendication 7, dans lequel la lectine est obtenue à partir de *Bandeirea simplicifolia*.
14. Agent selon les revendications 1-6, dans lequel la lectine est d'origine mammalienne.
15. Agent selon les revendications 1-6, dans lequel la lectine est obtenue à partir de bactéries.
16. Agent selon la revendication 15, dans lequel la lectine est obtenue à partir de *Pseudomonas aeruginosa*.
17. Agent selon une revendication précédente quelconque, dans lequel la lectine a été obtenue en utilisant la technologie des recombinants.
18. Agent selon une revendication précédente quelconque, dans lequel la lectine a été enzymatiquement modifiée.
19. Agent selon une revendication précédente quelconque, dans lequel la lectine a été modifiée chimiquement.
20. Agent selon une revendication précédente quelconque, dans lequel, si la chaîne lourde (chaîne H) d'une neurotoxine clostridiale est présente, le domaine H_C de la chaîne H est supprimé ou modifié.
21. Agent selon une revendication précédente quelconque, dans lequel la chaîne H, si elle est présente, est modifiée par dérivatisation chimique pour réduire ou supprimer son affinité native de fixation aux neurones moteurs.
22. Agent selon l'une quelconque des revendications 1-20, dans lequel la chaîne H, si elle est présente, est modifiée par mutation pour réduire ou supprimer son affinité native de fixation aux neurones moteurs.
23. Agent selon l'une quelconque des revendications 1-20, dans lequel la chaîne H, si elle est présente, est modifiée par protéolyse.
24. Agent selon la revendication 20, dans lequel, si la chaîne H est présente, le domaine H_C est complètement supprimé, en laissant seulement le fragment H_N d'une neurotoxine clostridiale.
25. Agent selon une revendication précédente quelconque, dans lequel le dérivé de la neurotoxine clostridiale, ou d'un fragment de celle-ci, est obtenu à partir de neurotoxine botulinique.
26. Agent selon une revendication précédente quelconque, dans lequel le dérivé de la neurotoxine clostridiale, ou d'un fragment de celle-ci, est obtenu à partir de neurotoxine botulinique de type A.
27. Agent selon les revendications 1-25, dans lequel le dérivé de la neurotoxine clostridiale, ou d'un fragment de celle-ci, est obtenu à partir de neurotoxine botulinique de type B.
28. Agent selon l'une quelconque des revendications 1, 2 ou 4-25 (sauf lorsqu'il dépend de la revendication 3), qui est formé par le couplage d'une lectine fixatrice de galactose au fragment LH_N de neurotoxine botulinique de type A.
29. Agent selon la revendication 28 qui est formé par le couplage de la lectine fixatrice de galactose provenant d'*Erythrina cristagalli* au fragment LH_N de neurotoxine botulinique de type A.
30. Agent selon la revendication 28 qui est formé par le couplage de la lectine fixatrice de galactose provenant d'*Erythrina corallodendron* au fragment LH_N de neurotoxine botulinique de type A.
31. Agent selon la revendication 28 qui est formé par le couplage de la lectine fixatrice de galactose provenant de *Glycine max* au fragment LH_N de neurotoxine botulinique de type A.
32. Agent selon une revendication précédente quelconque, dans lequel la chaîne H, si elle est présente, est obtenue à partir d'une neurotoxine clostridiale différente de celle à partir de laquelle la chaîne L

est obtenue.

33. Agent selon la revendication 32, dans lequel la chaîne H est obtenue à partir de neurotoxine botulinique de type A et la chaîne L à partir de neurotoxine botulinique de type B. 5
34. Agent selon la revendication 32, dans lequel la chaîne H est obtenue à partir de neurotoxine botulinique de type A et la chaîne L à partir de neurotoxine tétanique. 10
35. Agent selon les revendications 33 et 34, dans lequel le composant de la chaîne H est le fragment LH_N de neurotoxine botulinique de type A. 15
36. Agent selon une revendication précédente quelconque, dans lequel la chaîne L ou le fragment de chaîne L est lié(e) à la chaîne H, si elle est présente, par une liaison directe covalente. 20
37. Agent selon l'une quelconque des revendications 1-35, dans lequel la chaîne L ou le fragment de chaîne L est lié(e) à la chaîne H, si elle est présente, par une liaison covalente qui inclut une ou plusieurs régions d'espacement. 25
38. Agent selon une revendication précédente quelconque, dans lequel le dérivé de neurotoxine clostridiale incorpore des polypéptides produits par la technologie des recombinants. 30
39. Agent selon une revendication précédente quelconque, dans lequel la lectine est liée au composé dérivé de neurotoxine clostridiale par une liaison directe covalente. 35
40. Agent selon l'une quelconque des revendications 1-38, dans lequel la lectine est liée au composé dérivé de neurotoxine clostridiale par une liaison covalente qui inclut une ou plusieurs régions d'espacement. 40
41. Agent selon une revendication précédente quelconque, dans lequel la lectine et les composants provenant de neurotoxine clostridiale sont produits en tant que protéine de fusion recombinante. 45
42. Agent selon une revendication précédente quelconque, dans lequel la protéine de lectine a été modifiée par rapport à sa séquence polypeptidique native, tout en conservant une capacité, de fixer les structures d'oligosaccharides, dans lesquelles le résidu terminal est dérivé de galactose ou N-acétylgalactosamine. 50
43. Agent selon la revendication 42, dans lequel la modification de la protéine résulte de la modification 55

du de l'acide nucléique codant pour la protéine de lectine par rapport à sa séquence native.

44. Procédé d'obtention d'un agent selon une revendication précédente quelconque, qui comprend la fixation covalente d'une lectine fixatrice de galactose à un dérivé d'une neurotoxine clostridiale, dans lequel le dérivé de la neurotoxine clostridiale comprend la chaîne L ou un fragment de chaîne L qui inclut le domaine protéolytique actif de la chaîne légère (L), lié à une molécule ou un domaine ayant une activité de translocation à travers la membrane. 5
45. Procédé d'obtention d'un agent selon l'une quelconque des revendications 1-43, qui comprend la fixation covalente d'une lectine fixatrice de galactose à un dérivé d'une neurotoxine clostridiale avec l'inclusion d'une ou de plusieurs régions d'espacement, dans lequel le dérivé de la neurotoxine clostridiale comprend la chaîne L ou un fragment de chaîne L qui inclut le domaine protéolytique actif de la chaîne légère (L), lié à une molécule ou un domaine ayant une activité de translocation à travers la membrane. 10
46. Procédé selon la revendication 44 ou 45, dans lequel le domaine de translocation à travers la membrane est dérivé de la chaîne lourde d'une toxine clostridiale. 15
47. Procédé selon la revendication 44 ou 45, dans lequel le domaine de translocation à travers la membrane est dérivé d'une source non clostridiale. 20
48. Procédé d'obtention d'un agent selon l'une quelconque des revendications 1-43, qui comprend la réalisation d'une construction génétique qui code pour l'agent, en incorporant cette construction dans un organisme d'accueil et en exprimant la construction pour produire l'agent. 25
49. Utilisation de l'agent selon l'une quelconque des revendications 1-43 pour la fabrication d'un médicament pour maîtriser la transmission d'informations sensorielles depuis un neurone afférent sensoriel primaire à un neurone cible. 30
50. Utilisation de l'agent selon l'une quelconque des revendications 1-43 pour la fabrication d'un médicament pour maîtriser la transmission d'informations sensorielles depuis un neurone afférent nociceptif primaire à un neurone cible. 35
51. Utilisation selon la revendication 49 ou la revendication 50, dans laquelle la transmission est la libération d'un neurotransmetteur ou neuromodulateur. 40
52. Utilisation de l'agent selon l'une quelconque des revendications 1-43 pour la fabrication d'un médica-

ment pour maîtriser la sensation de douleur.

53. Utilisation de l'agent selon l'une quelconque des revendications 1-43 pour la fabrication d'un médicament pour atténuer et/ou prévenir la douleur. 5

10

15

20

25

30

35

40

45

50

55

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7





Figure 8

Panel A: eDRG



Panel B: eSC neurons






Figure 9


A.



B.



C



D




Figure 10

